[Federal Register Volume 67, Number 102 (Tuesday, May 28, 2002)]
[Notices]
[Page 36905]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-13278]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Adult Human Dental Pulp 
Stem Cells In Vitro and In Vivo

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
U.S. Patent Application Serial No. 60/219,989, filed July 21, 2000, now 
converted into PCT application number PCT/US01/23053 filed July 23, 
2001 entitled, ``Adult Human Dental Pulp Stem Cells In Vitro and In 
Vivo,'' to Dentigenix, having a place of business in the state of 
Washington. The field of use may be limited to the treatment of dental 
regeneration. The United States of America is the assignee of the 
patent rights in this invention. This announcement is the first notice 
to grant an exclusive license to this technology.

DATES: Only written comments and/or application for a license, which 
are received by the NIH Office of Technology Transfer on or before July 
29, 2002 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Marlene Shinn, Technology Licensing Specialist, 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, MD 20852-3821; Telephone: 
(301) 496-7056, ext. 285; Facsimile: (301) 402-0220; e-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: This technology utilizes dental pulp stem 
cells wherein an adult individual's own dental pulp tissue (one or two 
wisdom teeth) can potentially be used to engineer healthy living teeth. 
Our scientists have isolated and characterized a subpopulation of cells 
within normal, human dental pulp tissue with the ability to grow and 
proliferate in vitro. These stem cells can be induced under defined 
culture conditions to form calcified nodules in vitro and have been 
shown to differentiate into specialized tissues.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: May 13, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 02-13278 Filed 5-24-02; 8:45 am]
BILLING CODE 4140-01-P